XLO
NASDAQXilio Therapeutics Inc.
News · 26 weeks30+300%
2026-04-192026-10-11
Mix990d
- Other3(33%)
- SEC Filings3(33%)
- Insider2(22%)
- Leadership1(11%)
Latest news
25 items- INSIDERSEC Form 4 filed by CHIEF MEDICAL OFFICER Houvras Yariv4 - Xilio Therapeutics, Inc. (0001840233) (Issuer)
- INSIDERSEC Form 3 filed by new insider Houvras Yariv3 - Xilio Therapeutics, Inc. (0001840233) (Issuer)
- PRXilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)WALTHAM, Mass., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (NASDAQ:XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for people living with cancer, today announced that, effective October 1, 2026, the company granted non-qualified stock options to purchase an aggregate of 100,895 shares of its common stock to two new employees under Xilio Therapeutics’ Third Amended and Restated 2022 Inducement Stock Incentive Plan (the 2022 Inducement Stock Incentive Plan). Additionally, the company granted a non-qualified stock option to purchase 105,000 shares of its common stock under the 2022 Inducement Stock Incentive Plan to the
- PRXilio Therapeutics Appoints Yariv J. Houvras, M.D., Ph.D. as Chief Medical OfficerWALTHAM, Mass., Sept. 28, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (NASDAQ:XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for people living with cancer, today announced the appointment of Dr. Yariv Houvras as chief medical officer. "We are thrilled to welcome Yariv at this exciting time for Xilio as we advance XTX501, our bispecific PD-1 / masked IL-2, in the clinic and our next generation of multi-specific, masked T cell engagers," said René Russo, Pharm.D., president and chief executive officer of Xilio. "Yariv is an accomplished physician-scientist with a proven track record of leading complex global clinical developmen
- PRXilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)WALTHAM, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (NASDAQ:XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for people living with cancer, today announced that, effective September 1, 2026, the company granted non-qualified stock options to purchase 19,865 shares of its common stock to two new employees under Xilio Therapeutics’ 2022 Inducement Stock Incentive Plan. The stock options have an exercise price of $8.88 per share, which is equal to the closing price of the company’s common stock on September 1, 2026. Each stock option has a ten-year term and will vest as to 25% of the shares underlying the stock o
- SECSEC Form S-8 filed by Xilio Therapeutics Inc.S-8 - Xilio Therapeutics, Inc. (0001840233) (Filer)
- SECSEC Form 10-Q filed by Xilio Therapeutics Inc.10-Q - Xilio Therapeutics, Inc. (0001840233) (Filer)
- SECXilio Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Xilio Therapeutics, Inc. (0001840233) (Filer)
- PRXilio Therapeutics Reports Second Quarter 2026 Financial Results and Provides Pipeline and Business UpdatesReceived FDA clearance of IND application for XTX501, a potential best-in-class bispecific PD-1 / masked IL-2 Advancing IND-enabling studies for potential first-in-class multi-specific, masked T cell engager programs targeting CLDN18.2 and PSMA+STEAP1; IND applications anticipated in the second half of 2027 Cash runway into the first quarter of 2028 expected to support key milestones across pipeline of next generation multi-specific I-O therapies WALTHAM, Mass., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (NASDAQ:XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for people living with cancer, today announced pipeline
- PRXilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)WALTHAM, Mass., July 06, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (NASDAQ:XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for people living with cancer, today announced that, effective July 1, 2026, the company granted non-qualified stock options to purchase 107,060 shares of its common stock to three new employees under Xilio Therapeutics’ 2022 Inducement Stock Incentive Plan. The stock options have an exercise price of $9.22 per share, which is equal to the closing price of the company’s common stock on July 1, 2026. Each stock option has a ten-year term and will vest as to 25% of the shares underlying the stock option on
- PRXilio Therapeutics Appoints Ben Harshbarger as Chief Legal OfficerWALTHAM, Mass., June 29, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (NASDAQ:XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for people living with cancer, today announced the appointment of Ben Harshbarger as chief legal officer. "Ben is a proven leader, with deep legal and strategic experience across all stages of biotechnology companies," said René Russo, Pharm.D., president and chief executive officer of Xilio. "He joins our leadership team at an important time at Xilio, as we advance our pipeline of next-generation, multi-specific I-O therapies toward the clinic, including XTX501, a potential best-in-class bispecific PD-1
- INSIDERSEC Form 4 filed by Director Shannon James Samuel4 - Xilio Therapeutics, Inc. (0001840233) (Issuer)
- INSIDERSEC Form 4 filed by Director Bonstein Sara4 - Xilio Therapeutics, Inc. (0001840233) (Issuer)
- INSIDERSEC Form 4 filed by Director Curran Daniel J.4 - Xilio Therapeutics, Inc. (0001840233) (Issuer)
- INSIDERSEC Form 4 filed by Director Xu Yuan4 - Xilio Therapeutics, Inc. (0001840233) (Issuer)
- INSIDERSEC Form 4 filed by Director Ross Robert W.4 - Xilio Therapeutics, Inc. (0001840233) (Issuer)
- INSIDERSEC Form 4 filed by Director Bello Akintunde Olatokumbo4 - Xilio Therapeutics, Inc. (0001840233) (Issuer)
- INSIDERSEC Form 4 filed by Director Brennan Aoife4 - Xilio Therapeutics, Inc. (0001840233) (Issuer)
- SECXilio Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits8-K - Xilio Therapeutics, Inc. (0001840233) (Filer)
- SECSEC Form EFFECT filed by Xilio Therapeutics Inc.EFFECT - Xilio Therapeutics, Inc. (0001840233) (Filer)
- SECAmendment: SEC Form S-3/A filed by Xilio Therapeutics Inc.S-3/A - Xilio Therapeutics, Inc. (0001840233) (Filer)
- SECSEC Form SCHEDULE 13G filed by Xilio Therapeutics Inc.SCHEDULE 13G - Xilio Therapeutics, Inc. (0001840233) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Xilio Therapeutics Inc.SCHEDULE 13G/A - Xilio Therapeutics, Inc. (0001840233) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Xilio Therapeutics Inc.SCHEDULE 13G/A - Xilio Therapeutics, Inc. (0001840233) (Subject)
- SECSEC Form S-3 filed by Xilio Therapeutics Inc.S-3 - Xilio Therapeutics, Inc. (0001840233) (Filer)
XLO FAQ
7 questionsWhat does Xilio Therapeutics Inc. do?
Xilio Therapeutics, Inc., a biotechnology company, designs immunotherapies to improve the immune system for cancer patients. Its checkpoint inhibitor programs include XTX101, is a clinical-stage, tumor-selective anti-CTLA-4 mAb that is in Phase 1 clinical trials in patients with solid tumors; and cytokine programs comprise XTX202, XTX301, and XTX401, which are modified form of IL-2 that is masked with a protein domain to prevent binding activity until cleaved off by tumor microenvironment (TME)-associated proteases. Xilio Therapeutics, Inc. was incorporated in 2020 and is headquartered in...Where does XLO stock trade?
Xilio Therapeutics Inc. (XLO) is listed on NASDAQ.What sector and industry is XLO in?
Xilio Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Xilio Therapeutics Inc. go public?
Xilio Therapeutics Inc. (XLO) completed its IPO in 2021.What are analysts saying about XLO?
Xilio Therapeutics Inc. has had 7 recent analyst actions on file. The most recent action was from Leerink Partners: Outperform with a $200.00 price target on 2025-08-06.What companies are similar to XLO?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare XLO side-by-side with any of them on Quantisnow.How can I track XLO on Quantisnow?
Quantisnow aggregates Xilio Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow XLO to receive live email and push alerts on every new disclosure.